CTOs on the Move

Verseon

www.verseon.com

 
Verseon is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.verseon.com
  • 48371 Fremont Blvd Ste 101
    Fremont, CA USA 94538
  • Phone: 510.225.9000

Executives

Name Title Contact Details

Similar Companies

BioInquire

BioInquire is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metrohm USA Inc

Metrohm USA Inc is a Riverview, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axol Bioscience

We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.

AsclepiX Therapeutics

AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.